Comparative Pharmacology
Head-to-head clinical analysis: CYCLESSA versus QUASENSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLESSA versus QUASENSE.
CYCLESSA vs QUASENSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.
Quetiapine antagonist at dopamine D2 and serotonin 5-HT2A receptors; also affects histamine H1 and adrenergic α1 and α2 receptors.
One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
100 mg orally every 12 hours.
None Documented
None Documented
Desogestrel: 38±13 hours (terminal); ethinyl estradiol: 14±3 hours (terminal). Steady-state reached after 7-10 days.
Terminal elimination half-life is 8–12 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); enterohepatic circulation.
Primarily renal excretion (approximately 70% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for about 20% (including metabolites); 10% undergoes metabolic clearance.
Category C
Category C
Oral Contraceptive
Oral Contraceptive